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ABSTRACT
Vascular endothelial growth factor A (VEGF-A) binding to the receptor
tyrosine kinase VEGFR2 triggers multiple signal transduction
pathways, which regulate endothelial cell responses that control
vascular development. Multiple isoforms of VEGF-A can elicit
differential signal transduction and endothelial responses. However,
it is unclear how such cellular responses are controlled by isoform-
specific VEGF-A–VEGFR2 complexes. Increasingly, there is the
realization that the membrane trafficking of receptor–ligand
complexes influences signal transduction and protein turnover. By
building on these concepts, our study shows for the first time that
three different VEGF-A isoforms (VEGF-A165, VEGF-A121 and
VEGF-A145) promote distinct patterns of VEGFR2 endocytosis
for delivery into early endosomes. This differential VEGFR2
endocytosis and trafficking is linked to VEGF-A isoform-specific
signal transduction events. Disruption of clathrin-dependent
endocytosis blocked VEGF-A isoform-specific VEGFR2 activation,
signal transduction and caused substantial depletion in membrane-
bound VEGFR1 and VEGFR2 levels. Furthermore, such VEGF-A
isoforms promoted differential patterns of VEGFR2 ubiquitylation,
proteolysis and terminal degradation. Our study now provides novel
insights into how different VEGF-A isoforms can bind the same
receptor tyrosine kinase and elicit diverse cellular outcomes.
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INTRODUCTION
Vascular endothelial growth factor A (VEGF-A) is a soluble ligand
that is essential for mammalian development and function
(Carmeliet et al., 1996; Ferrara et al., 1996; Koch et al., 2011).
VEGF ligands bind to a receptor tyrosine kinase (RTK) subfamily
termed vascular endothelial growth factor receptors (VEGFR1, 2
and 3), which regulate many aspects of vascular and lymphatic
development (Koch et al., 2011; Smith et al., 2015). The VEGF
family member VEGF-A binds a major receptor and membrane
glycoprotein (VEGFR2) expressed on endothelial cells and such
interactions facilitate signal transduction events that control
different aspects of vascular physiology. This VEGFR2 RTK is a
major regulator of new blood vessel sprouting i.e. angiogenesis
(Carmeliet, 2005; Koch and Claesson-Welsh, 2012).
Human VEGF-A is encoded by the VEGFA gene on locus
6p21.3 and contains at least eight exons and seven introns. The
VEGFA primary RNA transcript undergoes alternative splicing to
produce seven pro- and one anti-angiogenic isoforms of VEGF-A
(Harper and Bates, 2008). However, the reasons for this VEGF-A
isoform complexity and its conservation in mammalian species is
unclear. In general, work in this field has focused on the VEGF-
A165 isoform that is secreted by most animal cells and tissues;
nonetheless, it is clear that other VEGF-A isoforms elicit important
and distinct biological responses from endothelial cells (Harper and
Bates, 2008; Smith et al., 2015). The VEGF-A165 isoform programs
sequential steps in VEGFR2 tyrosine phosphorylation,
ubiquitylation, trafficking and proteolysis (Bruns et al., 2010;
Horowitz and Seerapu, 2012), linked to downstream signal
transduction events that trigger pro-angiogenic outcomes such as
cell proliferation, migration, tubulogenesis, vascular permeability
and leukocyte recruitment (Fearnley et al., 2014a; Koch et al.,
2011). Furthermore, VEGF-A isoforms differentially promote
VEGFR2-dependent signal transduction and cellular responses
(Fearnley et al., 2015, 2014a; Kawamura et al., 2008b; Pan et al.,
2007). However, the underlying mechanism(s) by which VEGF-A
isoforms act are still unclear, although VEGF-A isoform-specific
binding is implicated in recruiting a co-receptor called neuropilin 1
(NRP1) (Ballmer-Hofer et al., 2011; Harper and Bates, 2008;
Herzog et al., 2011; Kawamura et al., 2008a,b; Pan et al., 2007;
Tillo et al., 2015). This membrane receptor can bind both VEGF-
A165 and VEGF-A121 but only VEGF-A165 is believed to form a
trimeric complex with VEGFR2 and NRP1 (Koch et al., 2011).
The role of membrane trafficking in regulating receptor-ligand
function is becoming increasingly apparent (Bruns et al., 2010;
Horowitz and Seerapu, 2012). For example, VEGF-A165-stimulated
signal transduction requires co-ordination of VEGFR2 tyrosine
kinase activation with residence at different locations within the
endocytic pathway e.g. plasma membrane and endosomes
(Gourlaouen et al., 2013; Jopling et al., 2009; Koch et al., 2014;
Lanahan et al., 2013, 2010, 2014; Manickam et al., 2011;
Nakayama et al., 2013; Yamada et al., 2014; Zhang et al., 2013).
Plasma membrane VEGFR2 activation promotes recruitment of
phospholipase Cγ1 thus stimulating phosphatidylinositol-4,5-
bisphosphate (PIP2) hydrolysis to generate inositol-1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG): these molecules act
as second messengers that promote cytosolic calcium ion flux and
protein kinase C activation respectively (Meyer et al., 2003;
Takahashi and Shibuya, 1997; Wong and Jin, 2005). However,Received 3 February 2016; Accepted 8 March 2016
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VEGF-A-stimulated activation of theMAP kinase pathway is linked
to VEGFR2 residence in early endosomes (Bruns et al., 2010;
Jopling et al., 2009; Lampugnani et al., 2006; Lanahan et al., 2010).
An important question is whether VEGF-A isoforms have the
capacity to differentially ‘program’ VEGFR2 trafficking and
turnover that subsequently impacts on signal transduction and
endothelial cell responses. By combining biochemical and cell
biological approaches, our study finds that three different VEGF-A
isoforms (VEGF-A165, VEGF-A121 and VEGF-A145) stimulate
different patterns of VEGFR2 phosphorylation and internalization
into early endosomes, which subsequently impact on downstream
signal transduction events. Furthermore, such activated VEGFR2
polypeptides exhibit distinct patterns of ubiquitylation and
proteolysis. Our work now shows that VEGF-A isoform-specific
programming of VEGFR2 function is dependent on a combination
of post-translation modifications linked to residence time within
different compartments along the endocytic route.
RESULTS
VEGF-A isoforms promote differential signal transduction
and endothelial responses
VEGF-A binding to VEGFR2 activates multiple signal
transduction pathways (e.g. ERK1/2, Akt and p38 MAPK) with
evidence of VEGF-A isoform-specific cellular responses
(Fearnley et al., 2015, 2014a; Kawamura et al., 2008b; Pan
et al., 2007). Such intracellular signaling is dependent on
VEGFR2 tyrosine phosphorylation on cytoplasmic residues
such as Y951, Y1054, Y1059, Y1175 and Y1214 (Koch et al.,
2011; Smith et al., 2016). To test the idea that VEGF-A isoforms
trigger differential VEGFR2 activation, we monitored the
presence of such VEGFR2 phosphotyrosine-epitopes in human
umbilical vein endothelial cells (HUVECs) in response to
stimulation with different VEGF-A isoforms (1.25 nM; 0-
20 min) using immunoblot analysis (Fig. 1A). Quantification of
these immunoblot data revealed that these three VEGF-A
isoforms had differential capacities to promote the appearance
of the VEGFR2-pY1175 epitope (Fig. 1B). However, another
VEGFR2 phosphotyrosine epitope, pY1214, showed relatively
similar profiles in response to VEGF-A isoform stimulation
(Fig. 1C). Surprisingly, we discovered that significant levels of
VEGFR2-pY1214 already existed in non-stimulated endothelial
cells; furthermore, there was a relatively modest ∼2-fold rise in
VEGFR2-pY1214 levels in response to any of the VEGF-A
isoforms tested (Fig. 1A,C). Notably, the kinetics of VEGFR2-
pY1214 levels displayed a more sustained profile (Fig. 1C),
suggesting a more long-lived regulatory function.
Such findings raised the question whether other VEGFR2
phosphotyrosine epitopes exhibit distinct or different kinetic
profiles. To evaluate this aspect, we monitored the appearance
and kinetics of the VEGFR2-pY951, VEGFR2-pY1054 and
VEGFR2-pY1059 epitopes using site-specific antibodies
(Fig. 1A). All three VEGFR2 phosphotyrosine epitopes exhibited
similar kinetics and profiles in response to stimulation with the
VEGF-A165 isoform (Fig. S1A-C). Further analysis of these
VEGFR2 phosphotyrosine epitopes in response to VEGF-A121
and VEGF-A145 isoform stimulation revealed ∼2-5-fold reduced
signals with subtle profile differences (Fig. S1A-C). To examine
signaling events downstream of VEGFR2-pY1175, we analyzed the
phosphorylation and subsequent activation of Akt and ERK1/2
(Koch et al., 2011) (Fig. 1D). We found that the VEGF-A165
isoform promoted the highest increase in either Akt (Fig. 1E) or
ERK1/2 (Fig. 1F) phosphorylation in comparison to the other
VEGF-A isoforms. However, we noted that although VEGF-A121
was more effective (than VEGF-A145) in elevating VEGFR2-
pY1175 (Fig. 1B) and Akt-pS473 (Fig. 1E) levels, both VEGF-A121
and VEGF-A145 caused relatively similar levels of phospho-ERK1/
2 (Fig. 1F). One possible explanation for such effects is that VEGF-
A isoform-specific programming of VEGFR2 phosphotyrosine
epitopes is not the sole event(s) in controlling downstream signal
transduction and subsequent cellular response(s).
In endothelial cells, VEGF-A-stimulated signal transduction
through the Akt and ERK1/2 pathways is linked to increased cell
permeability and proliferation respectively (Koch et al., 2011; Lal
et al., 2001; Pedram et al., 1998; Six et al., 2002; Takahashi et al.,
2001). To determine whether VEGF-A isoform-specific signal
transduction differentially regulates such cellular responses,
endothelial cells were subjected to VEGF-A isoform stimulation
prior to the assessment of endothelial cell permeability and
proliferation (Fig. 1G,H). VEGF-A165 and VEGF-A121
stimulation promoted ∼1.8-fold increase in endothelial monolayer
permeability, and these effects were significantly higher than that
observed upon VEGF-A145 stimulation (Fig. 1G). Analysis of
endothelial cell proliferation upon VEGF-A165 isoform stimulation
revealed an ∼2-fold increase, which was consistently higher (∼25-
30%) than that observed upon either VEGF-A121 or VEGF-A145
stimulation (Fig. 1H). Additionally, VEGF-A121 and VEGF-A145
were comparable in their capacity to promote endothelial cell
proliferation (Fig. 1H). We also compared the ability of these
VEGF-A isoforms to stimulate endothelial cell migration, which
revealed that all three VEGF-A isoforms caused ∼2-fold increase in
cell migration with no isoform-specific effects (Fig. S2A,B). Other
unique VEGF-A-stimulated cellular responses include the
endothelial capacity to form tubules (tubulogenesis) or sprouts
from arterial slices. Here, stimulation with the VEGF-A165 isoform
was clearly the most effective at promoting endothelial
tubulogenesis (Fig. S2C,D) and aortic sprouts (Fig. S2E,F)
compared to the other two VEGF-A isoforms. Taken together,
such data supports the idea that unique features encoded by each
VEGF-A isoform enables the programming of specific patterns of
VEGFR2 activation linked to downstream signal transduction
events, which regulate endothelial cell responses.
VEGF-A isoforms cause differential plasma membrane-to-
endosome trafficking of VEGFR2
Recent studies have highlighted the importance of plasma
membrane-to-endosome trafficking in regulating VEGFR2
activation and downstream signal transduction (Gaengel and
Betsholtz, 2013; Gourlaouen et al., 2013; Lanahan et al., 2013,
2010; Nakayama et al., 2013). Our studies revealed that VEGF-A
isoforms have unique properties to stimulate VEGFR2 activation
and downstream signal transduction (Fig. 1); therefore, we
hypothesized that different VEGF-A isoforms could differentially
regulate VEGFR2 endocytosis. To test this idea, we assessed these
VEGF-A isoforms for their effects on the pools of VEGFR2 located
at the cell surface versus internal compartments using cell surface
biotinylation, affinity enrichment and quantitative immunoblotting
(Fig. 2A-C). Furthermore, we monitored the presence of VEGFR2-
pY1175 within the biotinylated VEGFR2 pool at the cell surface
(Fig. 2A). Quantification of these immunoblot data revealed that as
expected, all three VEGF-A isoforms promoted a significant rise in
cell surface VEGFR2-pY1175 levels, peaking at either 5 min
(VEGF-A165 and VEGF-A121) or 15 min (VEGF-A145) respectively
(Fig. 2B). Interestingly, cell surface VEGFR2-pY1175 levels were
significantly decreased after 30 min of VEGF-A165 or VEGF-A145
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stimulation (Fig. 2B). In contrast, VEGF-A121 caused a more long-
lived pool of VEGFR2-pY1175 at the cell surface that persisted for
at least 30 min (Fig. 2B). Both VEGF-A165 and VEGF-A145
produced similar kinetics of VEGFR2 endocytosis at the plasma
membrane; however, VEGF-A121-stimulated internalization of
VEGFR2 was clearly slower (Fig. 2C). These data suggest that
these VEGF-A isoforms have differential abilities in not only
promoting VEGFR2 activation but also causing plasma membrane-
to-endosome trafficking.
To assess the localization of VEGFR2 in intracellular
compartments in response to VEGF-A isoform stimulation, we
used quantitative immunofluorescence microscopy to monitor
VEGFR2 accumulation within early endosomes (Fig. 2D). By
evaluating VEGFR2 co-distribution with an early endosome
marker (EEA1), we discovered that either VEGF-A165 or VEGF-
A145 caused a similar ∼30% increase in VEGFR2 accumulation
within this compartment (Fig. 2E). In contrast, VEGF-A121
stimulation did not cause a significant increase in VEGFR2 co-
distribution with EEA1 (Fig. 2E). Taken together, these data
strongly support the view that VEGF-A isoforms have distinct
properties in programming VEGFR2 plasma membrane-to-
endosome trafficking.
Fig. 1. VEGF-A isoforms promote differential VEGFR2 phosphorylation and downstream signal transduction. (A) Endothelial cells were stimulated
with either VEGF-A165, VEGF-A121 or VEGF-A145 (1.25 nM) for 2.5, 5, 10 or 20 min before lysis and processing for immunoblot analysis using site-specific
phospho-antibodies against VEGFR2. (B,C) Quantification of VEGFR2-pY1175 (B) and VEGFR2-pY1214 (C) levels upon VEGF-A isoform stimulation.
(D) Endothelial cells were stimulated with either VEGF-A165, VEGF-A121 or VEGF-A145 (1.25 nM) for 5, 15, 30 or 60 min before lysis and processing for
immunoblot analysis of signal transduction. (E,F) Quantification of Akt-pS473 (E) and ERK1/2-pT202/pY204 (F) levels upon VEGF-A isoform stimulation.
(G,H) Endothelial cells were seeded into cellular assays to assess endothelial cell permeability bymeasuring trans-endothelial electrical resistance (TEER) (G) or
proliferation (H) upon control (Con) or VEGF-A165 (165), VEGF-A121 (121) or VEGF-A145 (145; 1.25 nM) stimulated conditions for 4 or 24 h respectively. Error bars
indicate ±s.e.m. (n≥4). *P<0.05, **P<0.01, ***P<0.001.
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VEGF-A isoforms programdifferential VEGFR2 ubiquitylation
and proteolysis
VEGF-A binding to VEGFR2 triggers distinct patterns of
ubiquitylation, proteolysis and clearance within the endosome-
lysosome system (Bruns et al., 2010, 2012; Ewan et al., 2006; Smith
et al., 2016). From our findings that VEGF-A isoforms had distinct
properties in regulating VEGFR2 endocytosis at the plasma
membrane, we predicted that VEGF-A-stimulated VEGFR2
degradation was isoform-specific. We confirmed that this was
indeed true: VEGF-A121 showed negligible effects on VEGFR2
Fig. 2. VEGF-A isoforms promote differential ligand-stimulated VEGFR2 internalization. (A) Endothelial cells were stimulated with either VEGF-A165,
VEGF-A121 or VEGF-A145 (1.25 nM) for 5, 15 or 30 min before cell surface biotinylation, affinity isolation and immunoblot analysis of whole cell lysates (WCL) or
biotinylated cell surface proteins (Affinity isolated). (B,C) Quantification of cell surface (B) activated VEGFR2-pY1175 or (C) mature total VEGFR2 levels upon
VEGF-A isoform stimulation. Transferrin receptor (TfR) was used as a loading control. (D) Endothelial cells were pre-treatedwith cycloheximide (CHX; 2 μg/ml) for
2 h prior to VEGF-A isoform stimulation (1.25 nM) for 30 min. Endothelial cells were fixed and processed for immunofluorescence microscopy; VEGFR2 (green),
EEA1 (red), nuclei (blue). Scale bar, 20 mm. (E) Quantification of VEGFR2/EEA1 co-distribution upon VEGF-A stimulation. Error bars indicate ±s.e.m. (n≥3).
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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degradation (Fig. 3A,B); however, VEGF-A165 or VEGF-A145
showed a similar ∼30% reduction in total VEGFR2 levels after
120 min (Fig. 3B).
Previous studies have shown that VEGFR2 undergoes 26S
proteasome-dependent proteolysis (∼30 min post-stimulation)
resulting in the appearance of ∼160 kDa VEGFR2-derived
proteolytic fragment (Bruns et al., 2010). In this context, one
possibility was that VEGF-A isoforms programmed different
patterns of VEGFR2 proteolysis. To test this idea, we subjected
endothelial cells to VEGF-A isoform stimulation for 30 or 120 min
and assessed VEGFR2 proteolysis by monitoring the presence
of this 160 kDa proteolytic fragment using immunoblotting
Fig. 3. VEGF-A isoform-specific regulation of ligand-stimulated VEGFR2 degradation, proteolysis and ubiquitylation. (A) Endothelial cells were
stimulated with either VEGF-A165, VEGF-A121 or VEGF-A145 (1.25 nM) for 5, 15, 30, 60 or 120 min before lysis and processing for immunoblot analysis to assess
total VEGFR2 levels. (B) Quantification of total VEGFR2 levels upon VEGF-A isoform stimulation. (C) Endothelial cells were stimulated with either VEGF-A165,
VEGF-A121 or VEGF-A145 (1.25 nM) for 30 or 120 min before lysis and processing for immunoblot analysis to assess VEGFR2 proteolysis. Black arrowheads
denote ∼160 kDa proteolytic fragment. (D) Quantification of VEGFR2 160 kDa proteolytic fragment (arrowheads in C) levels upon VEGF-A isoform stimulation.
(E) Endothelial cells were stimulated with either VEGF-A165, VEGF-A121 or VEGF-A145 (1.25 nM) for 15 or 30 min before being subjected to immunoprecipitation
using an antibody against total VEGFR2 (IP:VEGFR2). Whole cell (WCL) or IP:VEGFR2 lysates were processed for immunoblot analysis to assess VEGFR2
ubiquitylation status using an antibody against poly-ubiquitin (FK2). Tubulin or IgG were used as loading controls for WCL or IP lysates respectively.
(F) Quantification of VEGFR2 ubiquitylation status upon VEGF-A isoform stimulation. Error bars indicate ±s.e.m. (n≥3). *P<0.05, **P<0.01, ***P<0.001,
****P<0.0001.
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(arrowhead; Fig. 3C). Quantification of these data showed that all
three VEGF-A isoforms significantly promoted VEGFR2
proteolysis, with a peak at ∼30 min post-stimulation (Fig. 3D).
However, VEGF-A165 stimulation was the most effective at causing
VEGFR2 proteolysis (∼2.5-fold increase) compared to VEGF-A121
or VEGF-A145 (Fig. 3D). Interestingly, VEGF-A121 stimulation also
caused significant VEGFR2 proteolysis, which was higher than that
observed upon VEGF-A145 stimulation (Fig. 3D). One conclusion
drawn from these data is that a reduction in VEGFR2 endocytosis
does not immediately correlate with a reduction in proteolysis in
endosomes.
VEGF-A-stimulated VEGFR2 activation triggers increased
receptor ubiquitylation, which is implicated in targeting VEGFR2
for proteolysis and degradation (Bruns et al., 2010; Ewan et al.,
2006; Zhang et al., 2010). One possible explanation for the unique
properties of each VEGF-A isoform to program distinct patterns
of VEGFR2 proteolysis and degradation could be through
programming specific patterns of VEGFR2 ubiquitylation. To test
this idea, we subjected endothelial cells to different VEGF-A
isoforms stimulation, immunoisolated VEGFR2 and probed these
complexes for their ubiquitylation status via immunoblotting
(Fig. 3E). We found that VEGF-A165 stimulation promoted
maximal VEGFR2 ubiquitylation (Fig. 3E) corresponding to
∼3.5-fold increase (Fig. 3F). This ubiquitylation signal was
significantly greater than that caused by either VEGF-A121 or
VEGF-A145 stimulation (Fig. 3E,F). Interestingly, although VEGF-
A121 stimulation caused significant VEGFR2 ubiquitylation with a
different kinetic profile (Fig. 3F), VEGFR2 degradation was greatly
reduced (Fig. 3B). Contrastingly, a further finding is that although
VEGF-A145 promoted significant VEGFR2 degradation (Fig. 3B),
it did not cause a corresponding increase in VEGFR2 ubiquitylation
(Fig. 3E). Based on these data, we conclude that VEGFR2
ubiquitylation is not a prerequisite for degradation but could be
required for proteasome-regulated VEGFR2 cleavage on
endosomes.
Disruption of clathrin-dependent VEGFR2 trafficking, results
in the loss of isoform-specific signal transduction
Clathrin is an important structural protein that regulates clathrin-
dependent endocytosis at the plasma membrane (Robinson, 2015).
This endocytic route is further accessed byVEGFR2 complexes upon
VEGF-A stimulation (Bruns et al., 2010; Ewan et al., 2006;
Lampugnani et al., 2006). We hypothesized that targeted disruption
of clathrin-dependent endocytosis of VEGFR2would perturbVEGF-
A isoform-specific signal transduction. To test this idea, we depleted
clathrin heavy chain (CHC17) levels in endothelial cells using duplex
siRNAs directed at the mRNA. Such treatment caused a substantial
reduction in CHC17 protein levels (Fig. 4A). Unexpectedly,
depletion of CHC17 and perturbation of clathrin-dependent
endocytosis caused a substantial (>2-fold) decrease in VEGFR2-
pY1175 andVEGFR2-pY1214 levels caused by stimulationwith any
of the VEGF-A isoforms (Fig. 4A–C). This reduced activation was
also evident upon monitoring VEGF-A isoform-mediated activation
of either Akt (Fig. 4A,D) or ERK1/2 enzymes (Fig. 4A,E). One
major consequence occurring upon CHC17 depletion is a decrease in
steady-state VEGFR2 levels (Fig. 4A). Hence, one likely explanation
for the reduction in VEGFR2 activation and downstream signal
transduction upon clathrin depletion is a corresponding and
substantial depletion of VEGFR2 levels.
One question that was raised is whether other VEGFR2-regulated
signal transduction pathways are also affected by depletion of
CHC17 and perturbation of clathrin-dependent endocytosis.
Therefore, since different VEGF-A isoforms also cause
differential activation of p38 MAPK (Fearnley et al., 2015,
2014a; Kawamura et al., 2008a), we analyzed effects of CHC17
depletion on this signal transduction pathway (Fig. 4F).
Surprisingly and in contrast to previous findings, CHC17
depletion did not significantly affect the activation of the p38
MAPK pathway (Fig. 4F). Quantification of these data showed no
significant differences in VEGF-A isoform-specific p38 MAPK
activation between control or CHC-17-depleted conditions
(Fig. 4G). Notably, the relative magnitude of VEGF-A isoform-
specific p38 MAPK activation was also retained (Fig. 4G), in spite
of the substantial reduction in VEGFR2 levels upon CHC17
depletion (Fig. 4F). One conclusion is that clathrin-dependent
endocytosis regulates VEGF-A isoform-specific VEGFR2-
mediated turnover and signal transduction via Akt and ERK1/2
signal transduction pathways; however, VEGF-A-stimulated p38
MAPK signal transduction likely involves a VEGFR2 pool linked to
a different membrane trafficking pathway.
To evaluate the effects of perturbation of clathrin-dependent
endocytosis on the turnover of different membrane proteins, we
depleted clathrin heavy chain (CHC17) and examined the levels of
VEGFR2, VEGFR1 and NRP1 using immunoblotting (Fig. 5A). As
controls, we evaluated the turnover of the endosome-associated
transferrin receptor (TfR) and the trans-Golgi network marker
(TGN46) which are known to undergo recognition by clathrin-
associated machinery, endocytosis and delivery to endosomes
(Banting et al., 1998; Huang et al., 2004; Murphy et al., 2008; Owen
and Evans, 1998). Quantification of these data showed that CHC17
depletion (∼70% reduction) caused ∼60% reduction in VEGFR2 and
∼40% reduction in VEGFR1 levels (Fig. 5B). Interestingly, although
CHC17 depletion caused a reduction in membrane VEGFR1 levels,
soluble VEGFR1 levels were not significantly affected (Fig. 5A,B).
Furthermore, depletion of CHC17 and perturbation of clathrin-
dependent endocytosis did not affect the turnover of TfR, NRP1 or
TGN46 (Fig. 5A,B). One conclusion from these findings is that
clathrin-dependent endocytosis regulates the turnover of mature
membrane-bound VEGFR2 and VEGFR1 proteins. However, the
turnover of other membrane proteins such as NRP1, TfR and TGN46
are not affected by blocking clathrin-dependent endocytosis.
DISCUSSION
Our study shows, for the first time, that different VEGF-A isoforms
have unique properties in programming VEGFR2 endocytosis,
ubiquitylation and proteolysis. In our model, three different VEGF-
A isoforms can bind with similar affinity to the extracellular domain
of this RTK (VEGFR2) but differentially program the cytoplasmic
domain to acquire post-translational modifications, leading to
specific patterns of trafficking and proteolysis (Fig. 6). We now
suggest that activated VEGFR2 signified by acquisition of the
pY1175 epitope undergoes endocytosis and delivery to early
endosomes; such trafficking is essential for VEGF-A isoform-
specific activation of the Akt and ERK1/2 signal transduction
pathways (Fig. 6). This type of signal transduction is an essential
feature of how different VEGF-A isoforms regulate the endothelial
response that is central to the control of vascular physiology (Fig. 6).
Key lines of evidence support our conclusion that VEGF-A
isoforms differentially stimulate VEGFR2 endocytosis and delivery
to early endosomes (Fig. 6). Ligand-dependent VEGFR2
endocytosis was elevated in endothelial cells stimulated with
either VEGF-A165 or VEGF-A145. In contrast, VEGF-A121
displayed negligible effects in promoting VEGFR2 endocytosis.
One possible explanation lies in VEGF-A isoform-specific
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recruitment of VEGF co-receptors such as the neuropilins (NRP1,
NRP2), which are implicated in regulating VEGFR signal
transduction and trafficking (Ballmer-Hofer et al., 2011; Fearnley
et al., 2014a; Herzog et al., 2011; Lanahan et al., 2013; Pan et al.,
2007; Zachary, 2014). It has been proposed that both VEGF-A165
and VEGF-A121 can bind NRP1; however, only VEGF-A165 is
believed to form a heteromeric complex with VEGFR2 and NRP1
(Koch et al., 2011). Thus differential NRP1 recruitment into a
VEGFR2–VEGF-A complex depending on the VEGF-A isoform
involved could be a mechanism of programming signaling and
trafficking outcomes.
VEGFR2 trafficking is an essential regulatory component of
VEGF-A165-stimulated signaling events, with evidence for different
signal transduction pathways associated with the plasma membrane
Fig. 4. Depletion of clathrin heavy chain disrupts VEGF-A isoform-specific programing of Akt and ERK1/2, but not p38MAPK activation. (A) Endothelial
cells were subjected to scrambled (Scr) or clathrin heavy chain (CHC17)-specific siRNA duplexes, were stimulated with VEGF-A165 (165), VEGF-A121 (121) or
VEGF-A145 (145; 1.25 nM) for 0 or 15 min prior to cell lysis and processing for immunoblot analysis of signal transduction. (B-E) Quantification of VEGFR2-
pY1175 (B) and VEGFR2-pY1214 (C), Akt-pS473 (D) and ERK1/2-pT202/pY204 (E) levels upon VEGF-A isoform stimulation. (F) Endothelial cells were
subjected to scrambled (Scr) or clathrin heavy chain (CHC17)-specific siRNA duplexes, were stimulated with either VEGF-A165, VEGF-A121 or VEGF-A145
(1.25 nM) for 15 min prior to cell lysis and processing for immunoblotting. (G) Quantification of p38 MAPK-pT180/pY182 levels upon VEGF-A isoform stimulation.
Error bars indicate ±s.e.m. (n=3). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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and early endosomes (Gaengel and Betsholtz, 2013; Gourlaouen
et al., 2013; Lanahan et al., 2013, 2010; Nakayama et al., 2013). Our
study further extends such ideas as depletion of clathrin heavy chain
(CHC17) and perturbation of clathrin-dependent endocytosis
impaired Akt and ERK1/2 activation but did not affect the p38
MAPK pathway. Surprisingly, clathrin heavy chain depletion
caused ∼60% reduction in steady-state VEGFR2 levels but an
explanation for this remarkable effect is not clear. One possibility is
that multiple plasma membrane-associated VEGFR2 pools are
linked to different trafficking pathways that impact on VEGFR2
recycling and turnover. Here, perturbation of clathrin-dependent
endocytosis increases VEGFR2 proteolysis and turnover: increased
plasma membrane VEGFR2 accumulation could result with
association with clathrin-independent endocytosis pathways in
endothelial cells such as caveolae (Mukherjee et al., 2006) and
micropinocytosis (Muro et al., 2004). In contrast, a separate
VEGFR2 pool that exhibits different long-lived plasma membrane
dynamics couples VEGF-A binding to signal transduction via the
p38 MAPK pathway. VEGFR2 has been previously documented to
be also associated with clathrin-independent endocytic routes
(Labrecque et al., 2003). A logical conclusion is that VEGFR2
accumulation at the plasma membrane caused by a block in clathrin-
dependent endocytosis causes increased VEGFR2 trafficking (and
degradation) via an alternative route from the plasma membrane e.g.
caveolae and/or macropinocytosis.
An important discovery in this study is the finding that different
VEGF-A isoforms have the capacity to program distinct patterns of
VEGFR2 signal transduction and turnover. The VEGF-A145 and
VEGF-A165 isoforms have comparable properties in programming
VEGFR2 degradation; however, VEGF-A145 exhibits drastically
reduced capacity for promoting VEGFR2 tyrosine phosphorylation.
One explanation for these differences is that VEGF-A165 binding to
VEGFR2 subsequently promotes NRP1 recruitment, and this
heteromeric complex displays enhanced VEGFR2 recycling
(Ballmer-Hofer et al., 2011). Thus failure of VEGF-A145 to
promote NRP1 recruitment results in the shuttling of the
VEGFR2–VEGF-A145 complex from early endosomes towards late
endosomes and ultimately lysosomes for terminal degradation. In this
context, heparan sulfate proteoglycan is also postulated to act as a co-
receptor that modulates VEGF-A interactions with VEGFR2 and
subsequent functional outcomes (Cohen et al., 1995; Jakobsson et al.,
2006; Xu et al., 2011). Heparin-binding domains are present within
VEGF-A145 and VEGF-A165 whereas VEGF-A121 lacks this region.
These facts raise the possibility that heparan sulfate proteoglycan
recruitment to the VEGFR2–VEGF-A complex further modulates
signal transduction, trafficking and proteolysis events.
VEGFR2 ubiquitylation, proteolysis and terminal degradation is
strongly linked to endothelial cell responses in normal and disease
states (Bruns et al., 2010; Ewan et al., 2006; Pasula et al., 2012;
Shaik et al., 2012). However, our findings in this study now argue
that VEGFR2 ubiquitylation is not essential for controlled
degradation. In support of this idea, stimulation with VEGF-A145
promoted a substantial increase in VEGFR2 degradation
comparable to that induced by VEGF-A165, despite it stimulating
relatively low levels of VEGFR2 ubiquitylation. Therefore, we now
revise current models and suggest a mechanism whereby VEGFR2
ubiquitylation is a prerequisite for proteasome-regulated VEGFR2
cleavage on endosomes rather than lysosome-mediated terminal
degradation (Fig. 6). This proposed mechanism is further
strengthened by a recent study, which shows that VEGFR2 de-
Fig. 5. Depletion of clathrin heavy chain reduces basal VEGFR2 and mature VEGFR1 levels. (A) Endothelial cells were subjected to scrambled (Scr) or
clathrin heavy chain (CHC17)-specific siRNA duplexes, prior to cell lysis and processing for immunoblot analysis. (B) Quantification of basal VEGFR2, VEGFR1,
NRP1, transferrin receptor (TfR), TGN46 and CHC17 levels upon depletion of clathrin heavy chain (CHC17). Error bars indicate ±s.e.m. (n=3). **P<0.01,
***P<0.001, ****P<0.0001.
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ubiquitylation is functionally coupled to different proteolytic steps
on early endosomes (Smith et al., 2016). The selective proteolytic
cleavage of the activated and ubiquitylated VEGFR2 complex can
modulate communication to the ERK1/2 and Akt signal
transduction pathways (Bruns et al., 2010). Thus VEGF-A
isoform-specific VEGFR2 proteolysis and/or terminal degradation
could be a mechanism to program signal transduction downstream
of VEGFR2 in order to control diverse cellular responses.
An important finding in this study is that VEGF-A isoforms cause
differential phosphorylation of tyrosine residues within the
VEGFR2 cytoplasmic domain. A commonly postulated model is
that ligand-induced RTK dimerization enables one RTK
polypeptide to trans-phosphorylate the other ‘partner’ within the
complex (Endres et al., 2014; Kovacs et al., 2015; Lemmon and
Schlessinger, 2010; Lemmon et al., 2014). This is also postulated to
occur here with VEGF-A-stimulated VEGFR2 dimerization
promoting trans-autophosphorylation of multiple tyrosine
residues. We now find that different VEGF-A isoforms promote
distinct patterns of phosphorylation on VEGFR2 cytoplasmic
residues Y951, Y1054, Y1059 and Y1175. One unexpected
finding is the discovery that a phosphotyrosine epitope, VEGFR2-
pY1214, is already present at significant levels in resting or non-
stimulated cells. In contrast to other VEGFR2 phosphotyrosine
epitopes analyzed in this study, VEGF-A stimulation only caused a
modest twofold increase in VEGFR2-pY1214 levels with no
evident isoform-specific effects. One possible explanation is that
the VEGFR2-pY1214 epitope has a regulatory function(s) in the
quiescent RTK state. This idea is supported by transgenic mouse
studies where the VEGFR2-Y1175F germline mutation causes
embryonic lethality and resembles VEGFA (+/−) mice; however,
the VEGFR2-Y1214F mutant mice are viable and fertile (Sakurai
et al., 2005). Interestingly, the presence of the VEGFR2-pY1214
epitope is linked to p38 MAPK activation (Koch et al., 2011;
Lamalice et al., 2006); however, this view can be challenged by the
finding that the VEGF-A165, VEGF-A121 and VEGF-A145 isoforms
all cause comparable VEGFR2-pY1214 levels but promote
Fig. 6. Schematic depicting VEGF-A isoform-specific VEGFR2 trafficking and downstream signaling transduction. Upon ligand binding (1) VEGFR2
undergoes dimerization and either differential (Y1175) or comparable (Y1214) trans-autophosphorylation of specific tyrosine residues, depending on the VEGF-A
isoform used. (2) This results in distinct levels of receptor ubiquitylation (3) and internalization into EEA1-positive early endosomes. (4) Differential levels of VEGF-
A isoform-stimulated VEGFR2 internalization impacts on Akt and ERK1/2 activation in combination with VEGFR2-Y1175 phosphorylation. (5) From early
endosomes VEGFR2 is trafficked into late-endosomes where it under goes VEGF-A isoform-specific proteolysis prior to lysosomal degradation. (6) VEGF-A
isoform-specific VEGFR2 activation and receptor trafficking, mediates their individual capacities to regulate endothelial cell permeability, proliferation and blood
vessel formation. Size and magnitude of arrow denotes magnitude of response; red, reduced; green, increased.
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different levels of p38 MAPK activation. One explanation for this
discrepancy is that differential NRP1 recruitment to the VEGFR2–
VEGF-A complex is also linked to p38 MAPK activation and blood
vessel sprouting (Kawamura et al., 2008a). Thus the VEGF-A165
isoform-specific recruitment of NRP1 could account for its capacity
to promote increased p38 MAPK signal transduction. We conclude
that the two VEGFR2 phosphotyrosine-epitopes, pY1175 and
pY1214, have different functional roles within the VEGFR2
complex and act by integrating different aspects of signal
transduction, post-translational modifications and trafficking.
An emerging view is based on VEGF-A isoforms having unique
properties in programming VEGFR2 endocytosis, phosphorylation,
ubiquitylation, proteolysis and terminal degradation in lysosomes
(Fig. 6). We now provide an integrated mechanism to explain
how different VEGF-A isoforms regulate endothelial cell responses
such as cell permeability and proliferation. Our study now provides
novel insights into howmultiple VEGF-A isoforms bind to the same
RTK, yet elicit diverse biochemical and membrane trafficking
outcomes that influence the cellular response. A future challenge
will be to identify specific cytoplasmic factors that regulate the
differences in VEGF-A isoform-mediated VEGFR2 trafficking and
turnover. Such findings will provide a platform towards newways of
manipulating endothelial cell function in health and disease.
MATERIALS AND METHODS
Antibodies and growth factors
Antibodies: goat-anti-VEGFR1 (#AF321), goat-anti-VEGFR2 (#AF357),
rabbit-anti-phospho-VEGFR2-Y1214 (#AF1766) (R&D Systems,
Minneapolis, MN, USA), rabbit-anti-Akt (#9272S), rabbit-anti-phospho-
Akt (S473; #4060B), rabbit-anti-ERK1/2 (#9102S), mouse-anti-phospho-
ERK1/2 (T202/Y204; #9106S), rabbit-anti-neuropilin 1 (NRP1; #3725S),
rabbit-anti-phospho-VEGFR2-Y951 (#4991S), rabbit-anti-phospho-
VEGFR2-Y1059 (#3817S), rabbit-anti-phospho-VEGFR2-Y1175 (#2478S;
Cell Signaling Technology, Danvers, MA, USA), rabbit-anti-phospho-
VEGFR2-Y1054 (Clone D1W; #04-894; Merck Millipore, Watford, UK),
mouse-anti-α-tubulin (Clone DM1A; #T6199; Sigma Aldrich, Poole, UK),
mouse-anti-PECAM-1 (CD31; #sc-65260; Santa Cruz Biotechnology,
Dallas, TX, USA), mouse anti-ubiquitin (FK2; #14220; Caymen Chemical,
MI, USA), mouse-anti-clathrin heavy chain antibody (X22; #ab2731;Abcam,
Cambridge, UK), sheep-anti-TGN46 (#AHP500GT; AbD Serotec, Oxford,
UK). Endothelial cell growth medium (ECGM) was from PromoCell
(Heidelberg, Germany). Recombinant human VEGF-A165 was from
Genentech Inc. (San Francisco, CA, USA), both VEGF-A121 and VEGF-
A145 was from Promocell.
Cell culture and immunoblotting analysis
Human umbilical vein endothelial cells (HUVECs) were characterized as
previously described (Fearnley et al., 2014b; Howell et al., 2004). Cells were
seeded into 6-well plates and cultured (for at least 24 h) in ECGMuntil∼80%
confluent, washed three times with PBS and starved in MCDB131+0.2%
(w/v) BSA for 2-3 h. HUVECswere stimulated with 1.25 nMofVEGF-A for
the desired time period. Cells were washed three times with ice-cold PBS and
lysed in 2% (w/v) SDS in TBS containing 1 mMPMSFand protease inhibitor
cocktail (Sigma-Aldrich, Poole, UK). Protein concentration was determined
using the bicinchoninic acid (BCA) assay (Thermo Fisher, Loughborough,
UK). 15-25 µg of protein lysate was subjected to SDS-PAGE before analysis
by immunoblotting.
BrdU incorporation cell proliferation assay
2.5×103 endothelial cells were seeded per well of a 96-well plate and left to
acclimatize in ECGM overnight. Media was aspirated and cells starved in
MCDB131+0.2% BSA (w/v) for 2 h. Cells were stimulated with VEGF-A
isoforms (1.25 nM) in 100 µl total volumes for 24 h. 10 µM BrdU was
added per well 20 h post-stimulation. A cell proliferation ELISA (Roche
Diagnostics, Mannheim, Germany) was preformed according to
manufacturer’s instructions. The color change was developed using 3,3′
5,5′-tetramethylbenzidine solution and the reaction quenched with 1 M
H2SO4. Absorbance was measured at 450 nm using a Tecan Sunrise
multiwavelength 96-well plate reader (Mannedorf, Switzerland).
Assessment of endothelial monolayer permeability using trans-
endothelial electrical resistance (TEER)
Human endothelial cells were seeded at 5×104 cells/well into a 0.4 µm pore
size Transwell filter inserted into a 24-well plate (BD Biosciences, Oxford,
UK) in ECGM and cultured until a confluent monolayer was formed.
Transwells containing endothelial cells were then washed twice, transferred
to a fresh well containing 500 µl MCDB131+0.2% (w/v) BSA and starved
in 400 µl MCDB131+0.2% (w/v) BSA (added to the top each chamber) for
2 h. After 2 h (t=0 h) the trans-endothelial electrical resistance (TEER)
across each monolayer was measured using a MILLICELL-ERS TEER
machine (Merck Millipore). Following which, 100 µl of MCDB131+0.2%
(w/v) BSA containing the desired VEGF-A isoform was added to the upper
chamber. After a further 4 h (t=4 h) TEER across each monolayer was
measured again and the relative increase in permeability (corresponding to a
decrease in electrical resistance across the endothelial monolayer) was
calculated.
Cell migration assay
Endothelial cells were seeded at 3×104 cells/well into a 8 µm pore size
Transwell filter inserted into a 24-well plate (BDBiosciences) inMCDB131
+0.2% (w/v) BSA. MCDB131+0.2% (w/v) BSA containing the desired
concentration of VEGF-Awas added to the lower chambers to stimulate cell
migration. Cells were allowed to migrate for 24 h before being fixed and
stained with 0.2% (w/v) crystal violet in 20% (v/v) methanol. Non-migrated
cells were removed from the upper chamber using a moist cotton bud;
chambers were rinsed using double-distilled water. Three to five random
fields were imaged per Transwell filter and the average number of migratory
cells calculated.
Tubulogenesis assay
Primary human foreskin fibroblasts (Promocell) were cultured until
confluent in 48-well plates in Q333 fibroblast growth media (PAA
Laboratories, Pasching, Austria). 7500 endothelial cells were then seeded
per well onto the fibroblasts monolayer in a 1:1 mixture of Q333 and ECGM
and left to acclimatize for 24 h. Media was then aspirated and replaced with
fresh ECGM±VEGF-A isoform (1.25 nM) as desired; media was replaced
every 2-3 days for seven days. Co-cultures were then fixed in 200 µl 10% (v/
v) formalin for 20 min and blocked in 5% (w/v) BSA for 30 min at room
temperature. Co-cultures were then incubated with 1 µg/ml mouse anti-
human PECAM-1 (CD31; Santa Cruz, USA) overnight at 4°C. Cells were
washed three times with PBS before incubation with an anti-mouse Alexa
Fluor 594 conjugate (Invitrogen) for 3 h at room temperature. Wells were
then washed three times with PBS. Endothelial tubules were visualized by
immunofluorescence microscopy using an EVOS-fl inverted digital
microscope (Life Technologies, Paisley, UK). Five random fields were
imaged per well. Both the number of branch points and the total tubule
length was then quantified from each photographic field using the open
source software AngioQuant (www.cs.tut.fi/sgn/csb/angioquant) and
values averaged. For a more detailed method please see Fearnley et al.,
(2014b).
Aortic ring assay
Protocol adapted from previous studies (Baker et al., 2012). All procedures
involving animals and their tissues were carried out in accordance to UK
Home Office regulations and guidance at room temperature unless
otherwise stated. Briefly, male wild type C57BL/6 mice were sacrificed in
accordance with UK Home Office regulations. The thoracic aorta was
harvested from aortic arch to diaphragm. Fat and fascia were removed from
the aorta by sharp dissection and the vessel sliced into 0.5 mm rings. Aortic
rings were serum starved overnight at 37°C in 5 ml OptiMEM supplemented
with penicillin-streptomycin. On ice, purified type 1 rat tail collagen (Merck
Millipore) was diluted to 1 mg/ml with DMEM before adding 2 µl per ml of
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5 M NaOH. 55 µl of this embedding matrix was pipetted per well into a 96
well plate and aortic ring submerged within. Plates were incubated at room
temperature for 15 min before incubation at 37°C for 90 min. 150 µl
OptiMEM containing 2.5% (v/v) FCS and penicillin-streptomycin was
added per well with appropriate VEGF-A isoform (1.25 nM). Aortic rings
were incubated at 37°C for 5 days with a media change on day 3. Wells were
washed with 150 µl PBS containing 2 mM CaCl2 and 2 mM MgCl2 and
fixed in 4% formalin for 30 min. The collagen was permeabilized with three
15 min washes with PBS buffer containing 2 mM MgCl2, 2 mM CaCl2,
0.25% (v/v) Triton X-100. Rings were blocked in 30 µl 1% (w/v) BSA in
PBLEC (PBS containing 100 µMMnCl2, 1% (v/v) Tween-20, 2 mMCaCl2,
2 mMMgCl2) for 30 min at 37°C. 2.5 µg BS1 lectin-FITC (Sigma-Aldrich,
Poole, UK) in PBLEC was added per well and incubated overnight at 4°C.
Wells were washed three times with 100 µl PBS containing 2 mM MgCl2,
2 mM CaCl2 and 0.25% (v/v) Triton X-100 before incubation for 2 h with
1 µg/ml DAPI (in PBLEC). Wells were washed three times with 100 µl PBS
containing 0.1% (v/v) Triton X-100 and then with 100 µl sterile water.
Aortic sprouts were imaged using an EVOS-fl inverted digital microscope.
Number of initial sprouts (vascular sprouts emanating directly from the
aortic ring) were counted and averaged.
Cell surface biotinylation
Endothelial cells were stimulated (1.25 nMVEGF-A isoform in MCDB131+
0.2% (w/v) BSA) beforewashing twicewith ice-cold PBS and incubation with
0.5 mg/ml EZ-Link Sulfo-NHS-LC-Biotin (Thermo Fisher) in PBS containing
2 mMMgCl2 and 2 mMCaCl2 for 30 min at 4°C. Biotinylationwas quenched
by washing twice with ice-cold TBS followed by washing twice with ice-cold
PBS. Cells were lysed in 500 µl RIPA buffer for 1 h at 4°C. Lysates were
cleared by centrifugation at 16,000 g for 30 min at 4°C. Equivalent protein
amounts were incubated with 35 μl neutravidin-agarose beads (Thermo Fisher)
overnight at 4°C. Beads were pelleted by brief centrifugation, supernatant
removed and beads washed four times with 500 μl ice-cold RIPA buffer. 50 μl
of 2× SDS-PAGE sample buffer was added and proteins eluted via heating at
92°C for 10 min before SDS-PAGE and immunoblotting.
Immunofluorescence analysis
For immunofluorescence analysis, endothelial cells were serum starved in
MCBD131+0.2% (w/v) BSA for 2 h before being stimulated for 30 min
with desired VEGF-A isoform (1.25 nM). Endothelial cells were fixed and
processed as previously described (Bruns et al., 2010). Images were
acquired either using a wide-field deconvolution microscope DeltaVision
(Applied Precision Inc., Issaquah, USA). Relative VEGFR2 co-distribution
was quantified using Image J (NIH, Bethesda, USA) as previously described
(Bruns et al., 2010; Jopling et al., 2011).
VEGFR2 ubiquitylation analysis
Endothelial cells were stimulated (1.25 nM VEGF-A isoform in MCDB131
+ 0.2% (w/v) BSA; 2 wells per condition) before washing twice with ice-
cold PBS and lysed in RIPA buffer (150 mM NaCl, 50 mM Tris-HCl pH
7.4, 0.1% (w/v) SDS, 0.5% (w/v) sodium deoxycholate, 2 mM EDTA, 1%
(v/v) NP-40, 50 mM NaF) with freshly added 1 mM phenylmethylsulfonyl
fluoride (PMSF) and 10 mM iodoacetamide, and incubated for 5 min on ice
at 4°C. Lysates were cleared via centrifugation at 16,000 g for 30 min at
4°C. Equal concentrations of supernatant were incubated with VEGFR2
antibody for 2 h at 4°C. 35 µl of 50:50 Protein G-sepharose slurry
(Millipore, Watford, UK) was added and incubated overnight at 4°C. Beads
were pelleted by brief centrifugation, supernatant removed and beads
washed four times with 500 µl ice-cold RIPA buffer. 50 μl of 2× SDS-
PAGE sample buffer was added and proteins eluted by heating at 92°C for
10 min before SDS-PAGE and immunoblotting. VEGFR2 ubiquitylation
was monitored using mouse anti-FK2 antibody which detects both poly- and
mono-ubiquitylation.
Lipid-based transfection of siRNA duplexes
Cells were transfected with siRNA duplexes using lipofectamine
RNAiMAX (Invitrogen). Per well of a 6-well plate, 15 µl of 2 µM siRNA
duplexes was added to 481 µl of serum/antibiotic-free OptiMEM
(Invitrogen) and allowed to settle at room temperature for 5 min. 4 µl of
lipofectamine was then added and the mixture was inverted briefly and
incubated at room temperature for 20 min. HUVECs were seeded at 2.5×105
cells/ml in a 1 ml volume of OptiMEM, followed by immediate dropwise
addition of the siRNA/lipofectamine mixture. Cells were left at room
temperature for 30 min before being returned to the incubator. After 6 h total
incubation, media was replaced for ECGM. Cells were allowed to recover
for 72 h prior to treatment or processing for analysis. Scrambled siRNAwas
purchased as a siGENOME SMARTpool from Dharmacon (GE Healthcare,
Buckinghamshire, UK), clathrin heavy chain (CHC17) siRNA was from
Ambion (Life Technologies, Paisley, UK).
Scrambled siRNA target sequences: 5′-UAGCGACUAAACACAUC-
AA-3′, 5′-UAAGGCUAUGAAGAGAUAC-3′, 5′-AUGUAUUGGCCU-
GUAUUAG-3′, 5′-AUGAACGUGAAUUGCUCAA-3′. CHC17 siRNA
target sequence: 5′-GGGUGCCAGAUUAUCAAUU-3′.
Statistical analysis
This was performed using a one-way analysis of variance (ANOVA)
followed by Tukey’s post-hoc test or two-way ANOVA followed by
Bonferroni multiple comparison test using GraphPad Prism software (La
Jolla, CA, USA). Significant differences between control and test groups
were evaluated with P values less than 0.05 (*), 0.01 (**), 0.001 (***) and
0.0001 (****) indicated on the graphs. Error bars in graphs and histograms
denote ±s.e.m. (standard error of mean).
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